ROQ vs. OPTI, RLM, IMM, NSCI, ONC, CIZ, FAB, BVX, APTA, and GENF
Should you be buying Roquefort Therapeutics stock or one of its competitors? The main competitors of Roquefort Therapeutics include OptiBiotix Health (OPTI), Realm Therapeutics (RLM), ImmuPharma (IMM), NetScientific (NSCI), Oncimmune (ONC), Cizzle Biotechnology (CIZ), Fusion Antibodies (FAB), BiVictriX Therapeutics (BVX), Aptamer Group (APTA), and Genflow Biosciences (GENF). These companies are all part of the "biotechnology" industry.
Roquefort Therapeutics vs.
OptiBiotix Health (LON:OPTI) and Roquefort Therapeutics (LON:ROQ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, community ranking, profitability, valuation and risk.
4.9% of OptiBiotix Health shares are held by institutional investors. Comparatively, 1.7% of Roquefort Therapeutics shares are held by institutional investors. 12.0% of OptiBiotix Health shares are held by insiders. Comparatively, 60.4% of Roquefort Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
OptiBiotix Health received 145 more outperform votes than Roquefort Therapeutics when rated by MarketBeat users.
In the previous week, OptiBiotix Health had 1 more articles in the media than Roquefort Therapeutics. MarketBeat recorded 1 mentions for OptiBiotix Health and 0 mentions for Roquefort Therapeutics. OptiBiotix Health's average media sentiment score of 0.18 beat Roquefort Therapeutics' score of 0.00 indicating that OptiBiotix Health is being referred to more favorably in the media.
Roquefort Therapeutics has lower revenue, but higher earnings than OptiBiotix Health. OptiBiotix Health is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.
OptiBiotix Health has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Roquefort Therapeutics has a beta of 0.05, suggesting that its stock price is 95% less volatile than the S&P 500.
Roquefort Therapeutics' return on equity of -27.05% beat OptiBiotix Health's return on equity.
Summary
OptiBiotix Health beats Roquefort Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Roquefort Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roquefort Therapeutics Competitors List
Related Companies and Tools
This page (LON:ROQ) was last updated on 1/22/2025 by MarketBeat.com Staff
